ASCO: Bristol Myers adds to debate with Opdivo's presurgery lung cancer performance

In presurgery treatment of early-stage cancer, there has been much debate over whether the absence of cancer in surgically removed tissue serves as a good indicator of whether treatment will prevent cancer recurrence or death.